<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: November 30, 1999
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing the Company's appointment of David D. Shaw, Ph.D. as its vice
president of clinical research and technology development. The Press Release,
dated November 30, 1999, is attached as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated November 30, 1999, announcing
the Company's appointment of David D. Shaw, Ph.D. as its vice
president of clinical research and technology development
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
John Smolik, President
Date: December 1, 1999
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
No.
<S> <C>
99 Press release of the Company, dated November 30, 1999,
announcing the Company's appointment of David D. Shaw, Ph.D.
as its vice president of clinical research and technology
development
</TABLE>
<PAGE>
Exhibit 99
FOR IMMEDIATE RELEASE
PHOTOGEN APPOINTS DAVID D. SHAW, PH.D. VICE PRESIDENT,
CLINICAL RESEARCH AND TECHNOLOGY DEVELOPMENT
KNOXVILLE, TENN., NOV. 30, 1999 -- Photogen Technologies Inc. (NASDAQ: PHGN),
developers of non-invasive and minimally invasive diagnostics and therapies,
today announced the appointment of David D. Shaw, Ph.D., as the Company's
vice president of clinical research and technology development.
At Photogen, Dr. Shaw will be responsible for directing clinical trial
programs leading to Food and Drug Administration (FDA) approval of the
Company's advanced device and drug technologies. Dr. Shaw's initial efforts
will be focused on clinical trials related to the recently announced joint
venture with Elan Corporation, plc. The joint venture involves sentinel lymph
node mapping, a technique used to determine the degree that a tumor, related
to breast, prostate or lung cancer, has spread. The clinical development
group will be located in Boston, where Dr. Gerald Wolf, Photogen's medical
director, is located.
"With more than 20 years' experience in drug development, specifically in
diagnostic imaging and oncology, Dr. Shaw brings a tremendous amount of
experience and expertise to our clinical development group," said John
Smolik, Photogen president and CEO. "With his strong qualifications, we feel
confident that commercialization of our minimally invasive lymphography
product will proceed in a professional, timely manner."
"I look forward to being a part of the Company's innovative clinical
development group," said Dr. Shaw. "I believe the technologies Photogen is
pursuing will eventually improve the way we diagnose and treat cancer that
has spread to the lymph nodes."
Dr. Shaw joins Photogen following eight years with the pharmaceutical company
Nycomed Amersham Inc., where he was vice president, drug development for
Latin America and Canada. Dr. Shaw established and implemented new models of
international clinical trial processes and organized clinical sites in Latin
America and Canada for inclusion in worldwide clinical development programs.
<PAGE>
Dr. Shaw holds a bachelor's degree in zoology from the University of
Cincinnati, a master's degree in biology from Idaho State University, and a
doctorate in medical physiology and biophysics from the University of
Nebraska Medical Center.
About Photogen
Photogen Technologies, Inc. is a development-stage company focused on
creating therapeutic and diagnostic products based on its proprietary
multi-photon and other related technologies. The company has discovered new
methods for using energy from lasers, x-rays or other sources to activate
photoactive agents within tissue sufficient to produce a range of beneficial
therapeutic and diagnostic outcomes. These technologies involve methods,
materials and devices that may be used to produce light or other energy and
photoactive agents and to destroy diseased cells, remove tissue or identify
and diagnose disease. Photogen has U.S. patents and additional pending
applications in the U.S. and worldwide for certain of its proprietary
technology. The company has no products or operating revenue at this time.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks and uncertainties include: the ability of the company to
develop a product and obtain regulatory approval for its use; the ability of
the company to successfully market and sell any products and equipment; the
company's ability to manufacture products in sufficient quantities; the
company's ability to maintain intellectual property protection for its
proprietary products, to defend its existing intellectual property rights
from challenges by third parties, and to avoid infringing intellectual
property rights of third parties; unforeseen operating risks; the company's
ability to secure collaborative agreements with third parties for various
research, development, manufacturing, marketing and other functions;
competition; risks associated with the dependence on manufacturers of the
company's proposed products; the availability of capital to finance planned
activities; and the extent to which the clinicians performing the procedures
are able to obtain third-party reimbursement. These risks are qualified in
their entirety by cautionary language and risk factors set forth in the
company's filings with the Securities and Exchange Commission.
Media Contacts: Hilary Kaye or Joan Murray at Hilary Kaye Associates
(714) 426-0444 (PST)
or [email protected].
Investor Relations Contact: Jonathan Fassberg at The Trout Group
(212) 477-9007 (EST) or
[email protected].
###
